Background: The role of non-medical prescribers working in palliative care has been expanding in recent years and prescribers report improvements in patient care, patient safety, better use of health professionals' skills and more flexible team working. Despite this, there is a lack of empirical evidence to demonstrate its clinical and economic impact, limiting our understanding of the future role of non-medical prescribers within a healthcare system serving an increasing number of people with palliative care needs. Aim: We developed a unique methodology to establish the level of non-medical prescribers' activity in palliative care across England and consider the likely overall contribution these prescribers are making at a national level in this context in relation to medical prescribing. Setting/participants: All prescriptions for 10 core palliative care drugs prescribed by general practitioners, nurses and pharmacists in England and dispensed in the community between April 2011 and April 2015 were extracted from the Prescribing Analysis Cost Tool system. Design: The data were broken down by prescriber and basic descriptive analysis of prescription frequencies by opioid, non-opioids and total prescriptions by year were undertaken. To evaluate the yearly growth of non-medical prescribers, the total number of prescriptions was compared by year for each prescribing group. Results: Non-medical prescribers issued prescriptions rose by 28% per year compared to 9% in those issued by medical prescribers. Despite this, the annual growth in non-medical prescribers prescriptions was less than 1% a year in relation to total community palliative care prescribing activity in England. Impact on medical prescribing is therefore minimal.
• • The United Kingdom is considered a world leader in non-medical prescribing, and no other country has the same extended prescribing rights as the United Kingdom. • • While non-medical prescribing in disease-specific areas such as diabetes, asthma and heart disease continues to grow, less is known about non-medical prescribing activity in areas where patients have complex co-morbid conditions such as palliative care. • • Previous studies have found that as many as half of all qualified non-medical prescribers working in palliative care do not actually prescribe.
What this paper adds?
• • The number of prescriptions issued by nurse prescribers in community palliative care in England has doubled since 2012.
• • The increase in non-medical prescribing in palliative care is almost entirely attributable to prescriptions for opioid medications. • • Non-medical prescribers are now prescribing 7% of all medications issued in community palliative care.
Implications for practice, theory or policy
• • These data provide empirical evidence to demonstrate that non-medical prescribers working in palliative care are prescribing the full range of drugs at their disposal and proportionally more opioids than medical prescribers. • • The impact of non-medical prescribing in terms of proportion of overall prescriptions issued remains small. At the current rate of growth, it would be 20 years before non-medical prescribers were prescribing 25% of all drugs issued in community palliative care.
Background
The role of nurses and pharmacists in prescribing medicines has been expanding in recent years and the United Kingdom's current model of prescribing is widely regarded as being at the international forefront. 1 The original policy objectives for the development of non-medical prescribing (NMP) related to the principles set out in the National Health Service (NHS) Plan: 2 improvements in patient care, choice and access, patient safety, better use of health professionals' skills and more flexible team working across the NHS. In working towards these objectives, the NHS embarked on a graduated move to increase the scope and responsibilities of NMP. This has culminated in the opening of the British National Formulary (BNF) to independent nurse and pharmacist prescribers in 2006. In 2012, further legislative changes enabled nonmedical prescribers to prescribe controlled drugs within their competence. Essentially, nurses with an NMP qualification now have the same prescribing capabilities as doctors. There are now over 3000 pharmacists and over 73,000 nurse prescribers (including midwifes) representing around 6% and 10% of the pharmacist and nursing workforce, respectively, in England. 3, 4 Some of the benefits of NMP have been substantiated through research [5] [6] [7] and NMP continues to grow particularly in disease-specific areas such as diabetes, asthma, hypertension and chronic obstructive pulmonary disease (COPD). Several studies have identified that prescribing for patients with co-morbid conditions present challenges for non-medical prescribers, 5, 8, 9 raising questions about the potential future impact of NMP within a healthcare system serving an increasing number of older people with multiple long-term conditions.
Previous research exploring NMP has focussed almost exclusively on the views of the prescribers rather than empirical studies illustrating the growth and impact of NMP. [8] [9] [10] [11] There is concern that NMP is being driven by individual practitioners rather than organisational strategy, and only half of UK NHS Trusts have a strategy for the development of NMP. 3 One of the key recommendations of a national evaluation of NMP undertaken in 2011 was that it is necessary to gather and disseminate empirical evidence demonstrating the clinical and economic impact of NMP. 12 To date, this has not been achieved, possibly due to the methodological challenges that demonstrating clinical and economic impact present. Establishing the extent of prescribing activity nationally or within a specific patient population is challenging. Although the UK Nursing and Midwifery Council and the General Pharmaceutical Register both maintain a record of members who are qualified prescribers, they do not hold information about the clinical setting in which they work. It would seem logical that the annual growth in NMP activity is proportionate to the annual growth in qualified prescribers, but previous studies 13 have found that many qualified prescribers do not actually prescribe, and in some settings such as palliative care, the number of qualified non-medical prescribers not prescribing is as high as 50%. 9 This may in part be explained by palliative care being a particularly challenging speciality for non-medical prescribers due to many of the patients having complex co-morbid conditions and a high prevalence of pain. Non-medical prescribers were under-equipped to treat pain until the legislative changes permitting the prescribing of controlled drugs, such as opioids, were enacted. 14 These changes had the potential to transform the scope of NMP in palliative care and facilitate the delivery of effective comprehensive pain management -a central component of high-quality end-of-life care. Palliative care patients are therefore a particularly interesting population in which to examine the impact and growth of NMP.
The aims of this study were to establish the level of NMP activity in palliative care across England and consider the likely overall contribution these prescribers are making at a national level in this context in relation to medical prescribing. For this analysis, we have developed a unique study methodology to help us identify NMP of selected medicines used primarily within a palliative care context.
Methods

Source of data
This study used data derived from the Prescribing Analysis Cost Tool (PACT) system which is maintained by NHS Prescription Services and covers prescriptions prescribed by GPs, nurses and pharmacists in England and dispensed in the community. Within the PACT system, one prescription represents one packet/box of one medicine prescribed to one patient. Prescriptions issued by non-medical prescribers are identifiable by a unique prescriber code in the NHS dataset. The PACT system does not indicate the specific clinical setting within community care in which the prescriber is working. We therefore devised a methodological approach which extracted and analysed drugs specific to palliative care together with prescriber codes to identify prescriptions issued by both medical and non-medical prescribers. This approach aimed to identify prescriptions issued to patients in the context of palliative care.
Palliative care prescriptions
We worked with clinicians and pharmacists with palliative care expertise to identify a core 'basket' of drugs used almost exclusively in palliative care settings. This core basket of palliative care drugs were mapped against other sources related to prescribing in palliative cares, such as the BNF 15 and National Institute for Health and Care Excellence (NICE) guidelines for adult palliative care. 16 The core basket of drugs comprised injection forms of haloperidol, hyoscine butylbromide, hyoscine hydrobromide, midazolam and levomepromazine.
Opioids
Opioids are the mainstay of pain management in palliative care; 17 however, they are also used in the management of chronic non-cancer pain. To calculate the proportion of all opioid prescriptions issued that were attributable to prescribing in a palliative care context, we were guided by research evidence from a large recent cross-sectional study. 18 This showed that 87.8% of prescriptions for the opioids buprenorphine, fentanyl, morphine and oxycodone were for chronic pain rather than pain associated with end of life. We therefore requested these four drugs were added to our core palliative care basket and assigned 12% of the total number of medical prescriptions for these to palliative care prescribing, adjusting the number of prescriptions accordingly. One opioid that was exempt from this calculation was diamorphine injection. Diamorphine is the second most commonly used drug for pain relief at the end of life 19 and is not typically used for management of other chronic pain; therefore, it was not necessary to subject the numbers of prescriptions to the same adjustment.
Data extraction
The final core basket of palliative care drugs consisted of the following nine items: injectable forms of 
Analysis
Basic descriptive analysis of prescription frequencies is presented by opioid, non-opioids, and total prescriptions by year. To evaluate the yearly growth of NMP in relation to medical prescribing, the total number of prescriptions was compared by year for each prescribing group (NMP vs medical). Overall changes in the proportion of opioid prescribing compared to non-opioid prescribing between 2011 and 2015 are presented descriptively by prescriber group. Table 1 shows the number of prescriptions issued for the drugs on our palliative care list between 2011 and 2015. The total overall number of prescriptions issued by both medical and non-medical prescribers increased by 33% from 1,142,537 to 1,591,156 over the 4-year period. The number of prescriptions issued by nurse prescribers in the The average annual increase in NMP issued prescriptions for the drugs on our list was 28% compared to an average annual increase of 9% in those issued by medical prescribers. Despite this, the annual growth in NMP prescriptions was less than 1% a year in relation to total community palliative care prescribing activity in England. By 2015, non-medical prescribers were responsible for 6.7% of all prescriptions issued in community palliative care.
Results
Number of prescriptions issued
Types of drugs prescribed
We separated the non-opioid palliative care prescriptions (Haloperidol, Hyoscine Butylbromide, Hyoscine Hydrobromide, Levomeprom Maleate and Levomepromazine) from the opioid (buprenorphine, fentanyl, morphine and oxycodone, diamorphine) prescriptions issued by prescribers and charted the number of prescriptions issued for each group year on year ( Figure 1 ). The total number of opioid prescriptions issued increased approximately 30% each year (31% 2012-2013; 28% 2013-2014; and 33% 2014-2015) . In contrast, the number of non-opioid prescriptions issued by non-medical prescribers showed a similar trend initially with a 32% increase between 2012 and 2013. For subsequent years, however, the rate of increase slowed with a 12% increase between 2013 and 2014 and a 10% increase between 2014 and 2015. This indicates that the growth in the total number of prescriptions for the drugs on our list issued by non-medical prescribers over the 2011-2015 period is almost entirely attributable to an increase in opioid prescriptions.
We explored whether medical prescribing had followed the same trend. Figure 2 illustrates that in 2011, opioids accounted for approximately 66% of prescriptions issued by both medical and non-medical prescribers. For medical prescribers, this proportion remained stable (rising 1%-67% in 2015), whereas for non-medical prescribers by 2015 opioids represented 76% of their overall prescribing activity.
Discussion
This study set out to address a stated need 10,20 for data to establish the level of NMP activity at a national level and consider the likely overall contribution non-medical prescribers are making in relation to medical prescribing. To the best of our knowledge, no previous studies have attempted to quantify prescribing longitudinally in a specific patient population, and consequently, it was necessary to design and pilot a novel methodological approach to achieve this. The approach we have taken could be adapted using a core list of drugs specific to other patient populations to determine the extent of NMP in other contexts.
We have identified that despite year-on-year growth in the number of prescriptions issued by non-medical prescribers in palliative care, the proportion in relation to medical prescribing remains relatively small. At the current rate of growth, it would be 20 years before non-medical prescribers were prescribing 25% of all drugs issued in community palliative care.
The number of strong opioid prescriptions issued by non-medical prescribers started to increase following the 2012 legislative changes 14 permitting non-medical prescribers to independently prescribe controlled drugs. The growth in opioid prescribing suggests non-medical prescribers have, at least to some extent, embraced the opportunity. In contrast, prescriptions for non-opioid medications remained relatively stable. This may reflect the fact that pain is the most prevalent symptom in endof-life care, 17 and as non-medical prescribers now have the authority to prescribe appropriate medication, it might be expected to constitute a growing proportion of their prescribing activity.
In terms of the impact of NMP on the quality of patient care, we have considered whether from our data we can determine whether NMP could be helping achieve the national objective of improving pain control at the end of life 21 and the original policy objectives of implementing NMP 22 to enable faster more responsive access to medications and relieve some of the prescribing burden from medical colleagues. While this study cannot determine whether NMP has influenced the timing of access to medication, our data provide empirical evidence to demonstrate non-medical prescribers are prescribing the full range of drugs at their disposal and supports the finding of previous studies into the benefits of the NMP role in palliative care and other healthcare contexts. 7, 8, 11 It therefore seems plausible that NMP could be helping improve pain control at the end of life.
In terms of whether NMP appears to be relieving some of the prescribing burden borne by medical colleagues, our data indicate that non-medical prescribers are substituting for medical prescribing activity in palliative care at a rate of 1% each year. Impact on medical prescribing (in terms of number of prescriptions issued) is therefore minimal so far and the ability to increase this impact is made more difficult by the current growth in the palliative care population which creates an ever increasing demand for prescriptions.
Our study has some limitations due to the nature of NHS prescribing data and it's separateness from other clinical information systems. Nevertheless, our study has importantly revealed, for the first time, how the profile of NMP prescribing has changed over a 4-year period during which a major policy change was introduced. It is arguable whether the number of prescriptions issued provides an accurate reflection on the impact of the NMP role. Earlier studies 8, 23 have found that the role of non-medical prescribers working in palliative care extends beyond initiating and issuing prescriptions: prescribers reported a significant proportion of 'prescribing' time is spent reviewing and rationalising current medication, discontinuing drugs and titrating doses. Polypharmacy is common in end-of-life care, and minimising adverse effects by reviewing and discontinuing unnecessary or contraindicated medication is an important NMP activity which data on prescriptions issued fail to capture.
Conclusion
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